These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28681435)

  • 1. Impact of lenalidomide-based induction therapy on the mobilization of CD34
    Partanen A; Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Putkonen M; Sankelo M; Pelkonen J; Mäntymaa P; Varmavuo V; Jantunen E
    Transfusion; 2017 Oct; 57(10):2366-2372. PubMed ID: 28681435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
    Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E
    Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of CD34
    Anu P; Antti T; Raija S; Marja P; Jaakko V; Timo S; Mervi P; Marja S; Anu S; Karri P; Taru K; Jukka P; Pentti M; Esa J; Ville V
    Transfusion; 2021 Nov; 61(11):3202-3212. PubMed ID: 34498764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
    Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
    Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
    Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
    Nazha A; Cook R; Vogl DT; Mangan PA; Gardler M; Hummel K; Cunningham K; Luger SM; Porter DL; Schuster S; O'Doherty U; Siegel D; Stadtmauer EA
    Bone Marrow Transplant; 2011 Jan; 46(1):59-63. PubMed ID: 20421869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
    Costa LJ; Abbas J; Hogan KR; Kramer C; McDonald K; Butcher CD; Littleton A; Shoptaw K; Kang Y; Stuart RK
    Bone Marrow Transplant; 2012 Nov; 47(11):1403-8. PubMed ID: 22484324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.
    Musto P; Simeon V; Grossi A; Gay F; Bringhen S; Larocca A; Guariglia R; Pietrantuono G; Villani O; D'Arena G; Cuomo C; Musto C; Morabito F; Petrucci MT; Offidani M; Zamagni E; Tacchetti P; Conticello C; Milone G; Palumbo A; Cavo M; Boccadoro M
    Stem Cell Res Ther; 2015 Apr; 6(1):64. PubMed ID: 25889496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
    Mark T; Stern J; Furst JR; Jayabalan D; Zafar F; LaRow A; Pearse RN; Harpel J; Shore T; Schuster MW; Leonard JP; Christos PJ; Coleman M; Niesvizky R
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):795-8. PubMed ID: 18541199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
    Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Gastineau DA; Litzow MR; Fonseca R; Roy V; Rajkumar SV; Gertz MA
    Leukemia; 2007 Sep; 21(9):2035-42. PubMed ID: 17581613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
    Micallef IN; Ho AD; Klein LM; Marulkar S; Gandhi PJ; Calandra G; McSweeney PA
    Bone Marrow Transplant; 2011 Mar; 46(3):350-5. PubMed ID: 20479709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.
    Turunen A; Silvennoinen R; Partanen A; Valtola J; Siitonen T; Putkonen M; Sankelo M; Pyörälä M; Kuittinen T; Penttilä K; Sikiö A; Savolainen ER; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Transfusion; 2021 Jun; 61(6):1830-1844. PubMed ID: 33955591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
    Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.
    Silvennoinen R; Anttila P; Säily M; Lundan T; Heiskanen J; Siitonen TM; Kakko S; Putkonen M; Ollikainen H; Terävä V; Kutila A; Launonen K; Räsänen A; Sikiö A; Suominen M; Bazia P; Kananen K; Selander T; Kuittinen T; Remes K; Jantunen E
    Bone Marrow Transplant; 2016 Mar; 51(3):372-6. PubMed ID: 26437056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.